Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany Joins Decision To Suspend AZ Vaccine Over Safety, But Is It Really The Most ‘Cautious’ Approach?

Countries At Odds With EMA Guidance

Executive Summary

AstraZeneca’s vaccine is under suspicion again, this time over safety, rather than efficacy, and the European Medicines Agency has promised a swift review.

You may also be interested in...



AstraZeneca CEO Rues Reality Of Vaccine Inequity

The UK major’s hopes of creating a vaccine for the world during the COVID-19 pandemic have been hampered by political self-interest and nationalism, according to a BBC documentary.

AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors

Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.

Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel